The ADD1 antibody targets adducin 1 (α-adducin), a cytoskeletal protein encoded by the *ADD1* gene. Adducins are heteromeric proteins (α, β, γ isoforms) that regulate actin-spectrin assembly, maintaining cell membrane integrity and stability. ADD1. specifically, plays a critical role in forming the spectrin-actin network, influencing cell-cell adhesion, ion transport, and signal transduction. It interacts with membrane proteins like Na+/K+-ATPase and modulates renal sodium handling, linking it to hypertension pathophysiology. Genetic variants (e.g., Gly460Trp) in *ADD1* are associated with salt-sensitive hypertension and cardiovascular risks.
The ADD1 antibody is widely used in research to study protein expression, localization, and interactions via techniques such as Western blotting, immunohistochemistry, and immunoprecipitation. It helps investigate ADD1's role in cellular mechanotransduction, renal function, and disease mechanisms. Dysregulation of ADD1 has been implicated in cancers, neurological disorders, and erythrocyte membrane defects, making its antibody a vital tool for exploring therapeutic targets. Commercial antibodies are typically validated for specificity against human, mouse, or rat ADD1. aiding cross-species comparative studies. Its application advances understanding of cytoskeletal dynamics and their implications in systemic diseases.